Molecular Signature to Risk-Stratify Prostate Cancer of Intermediate Risk
暂无分享,去创建一个
[1] Jennifer R. Rider,et al. Prognostic Utility of a New mRNA Expression Signature of Gleason Score , 2016, Clinical Cancer Research.
[2] M. Cooperberg,et al. Application of a Clinical Whole-Transcriptome Assay for Staging and Prognosis of Prostate Cancer Diagnosed in Needle Core Biopsy Specimens. , 2016, The Journal of molecular diagnostics : JMD.
[3] David Y. Lu,et al. Magnetic resonance imaging-ultrasound fusion biopsy for prediction of final prostate pathology. , 2014, The Journal of urology.
[4] P. Febbo,et al. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. , 2014, European urology.
[5] E. Crawford,et al. Cell cycle progression score and treatment decisions in prostate cancer: results from an ongoing registry , 2014, Current medical research and opinion.
[6] Anirban P. Mitra,et al. Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population. , 2013, The Journal of urology.
[7] M. Cooperberg,et al. Active surveillance for prostate cancer: a systematic review of the literature. , 2012, European urology.
[8] T. Golub,et al. mRNA expression signature of Gleason grade predicts lethal prostate cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] J. Cuzick,et al. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. , 2011, The Lancet. Oncology.
[10] Kirsten L. Greene,et al. Outcomes of active surveillance for men with intermediate-risk prostate cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.